$GILD Recent Headlines Medtronic’s real problem is

New Post Public Reply Private Reply Replies (0) Message Board

Jun 20, 2014 at 11:04 PM

$GILD Recent Headlines

Medtronic’s real problem is innovation, not taxation 6:45 a.m. June 19, 2014 - Tim Mullaney
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. June 18, 2014 - blogs.marketwatch.com
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis

AstraZeneca's Naloxegol Data Published - Analyst Blog 6:00 p.m. Today - Zacks.com
Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog 4:45 p.m. Today - Zacks.com
Dividend Yield Vs. Dividend Growth Revisited - Does It Matter? 4:26 p.m. Today - Seeking Alpha
OncoMed's OMP-54F28 on Partial Clinical Hold - Analyst Blog 3:50 p.m. Today - Zacks.com
Merge Healthcare: Updated Research Report - Analyst Blog 2:55 p.m. Today - Zacks.com
3 Stocks Reiterated As A Buy: DIS, BIDU, GILD 2:44 p.m. Today - TheStreet.com
Illumina: Updated Research Report - Analyst Blog 2:30 p.m. Today - Zacks.com
Achillion Could Win Idenix's Mystery Suitor: Analyst 11:44 a.m. Today - Investors Business Daily
Celgene Rises on Yet Another Stock Split - Analyst Blog 11:30 a.m. Today - Zacks.com
Cubist Gets Priority Review from FDA for Antibiotic Candidate - Analyst Blog 11:00 a.m. Today - Zacks.com
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms 10:25 a.m. Today - Seeking Alpha
Celgene Rally Is for Real 9:11 a.m. Today - Barrons.com
Cramer's Lightning Round - I Always Come Back To Palo Alto Networks (6/19/14) 6:35 a.m. Today - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Stryker 6:00 a.m. Today - TheStreet.com
'Mad Money' Lightning Round: Buy, Buy, Buy Stryker 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Management Matters, Not the Fed 7:57 p.m. June 19, 2014 - TheStreet.com
Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog 6:15 p.m. June 19, 2014 - Zacks.com
BioLineRx to Commence BL-8040 Study - Analyst Blog 6:10 p.m. June 19, 2014 - Zacks.com
Valeant Launches Hostile Bid for Allergan - Analyst Blog 5:50 p.m. June 19, 2014 - Zacks.com
Vertex Pharmaceuticals-Johnson & Johnson Collaborate on Flu Drug - Analyst Blog 5:00 p.m. June 19, 2014 - Zacks.com

Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert 6:15 a.m. June 11, 2014 - Marketwire
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10 5:00 p.m. June 9, 2014 - BusinessWire - BZX
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. June 3, 2014 - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flyers Fundraiser Supports Mental Health Advocacy in NJ and PA

Blockbusters on Ice, Support Beyond the Rink Here's a twist for hockey fans out there: snagging tickets to catch the Philadelphia Flyers might pack more punch off the ice than on it. Why? Because, for every ticket you grab through Digital Elements Group's special link, $5 is pumped straight into the veins of mental health advocacy in New Jersey and Pennsylvania. Pretty...

Immunofoco’s Lentiviral Strategy for Cancer Control

Revolutionizing Cancer Treatment: Immunofoco's Approach In the battle against B-cell malignancies, the old ways of doing things sometimes just don’t cut it, folks. Enter Immunofoco. At the recent Society for Immunotherapy of Cancer (SITC) 2026 meeting, they laid some ambitious cards on the table with their in vivo T-cell engager (TCE) delivery strategy. Engineering...

Day Out Snacks Brings Back Sold-Out Peppermint Bark

Spicing Up the Holidays with a Best-Seller Return You've got to love when a brand nails it in the holiday treat department, and Day Out Snacks is playing a winning hand by bringing back their Peppermint Bark protein balls. Here we are again, one year after they flew off the shelves like Santa spotted on Christmas Eve. And let me tell you, this re-release has the potential...

EASEL 360: Reinventing Comfort in Painting Tools

Artists, listen up—particularly those who are tired of the usual rigmarole that comes with traditional easels. There's a fresh tool coming down the pike, and it's set to make your painting experience a whole lot friendlier. Meet the EASEL 360, a patent-pending innovation birthed by two inventive folks from Streetsboro, Ohio. No longer will you have to contort yourself...

Ares Management Faces Fintech with $691B Assets

Anticipation Builds: Ares Awaits TD Cowen Spotlight Ah, Ares Management, the Wall Street heavyweight clocking a colossal $691 billion in assets. Now, they’re angling to dish out some strategic insights. With the TD Cowen 2026 Financials & Fintech Conference set to roll on November 18, what’s better than watching these investment titans take the stage with their CFO...

HitPaw's 2026 Black Friday Blitz: Up to 70% Savings

HitPaw Edimakor Throws Down the Gauntlet Alright, hit the brakes and take a look at what HitPaw Edimakor's cookin' up this Black Friday. These folks have come swinging with a sale that's got the kind of numbers that make you do a double-take. They're laying out discounts up to 70% across their lineup of video editing and AI tools. Deals That Pack a Punch First up, they've...

Eagle Bank Club Breathing New Life Into Historic Site

Preserving History with Contemporary Flair Sometimes, a building is more than just bricks and mortar, it's the heart of a community's memories. Come spring 2027, Eagle Bank Club is set to throw open its doors, reviving the century-old tradition of gathering in a place that's been etched into the town's identity. Scott Slater and Todd Ketlinski aren't just opening another...

Key Insights Await in Sectra's Six-Month Report

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Full Sail's Reach Expands with Film School Honor

Full Sail's Cinematic Spotlight Moment Alright, folks, you're hearing it right: Full Sail University's caught the spotlight in TheWrap Magazine's annual who's-who of film schools for 2026. That's a pat on the back any educational institution would kill for, highlighting that Full Sail is playing with the big boys when it comes to film education. Beyond Classic Classroom...

Kevlar® EXO™ Revolutionizes FIA Fuel Tank Standards

A New Era in Motorsport Safety Arclin and Aero Tec Laboratories (ATL) are shaking up the motorsport world. Through their collaboration, they've achieved something that's been untouched for over 25 years—meeting the rigorous new FIA 8875-2025 standards. It's all thanks to Kevlar® EXO™, a cutting-edge material redefining what's possible in fuel tank safety. Breaking...